Skip to main content

Table 1 Characteristics of patients with infective endocarditis

From: DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

 

N = 34

Age, median (IQR)

73 (63–81)

Male, n (%)

25 (73.5)

Charlson index, n (%)

2 (1–4)

Type of infection, n (%)

 Definite IE

31 (91.2)

 Probable IE

3 (8.8)

Endocarditis, n (%)

 Native

11 (32.4)

 Early prosthetic

5 (14.7)

 Late prosthetic

10 (29.4)

 Pacemaker lead

8 (23.5)

Valve affected, n (%)

 Aortic

17 (50)

 Mitral

8 (23.5)

 Tricuspid

1 (2.9)

Causative organism, n (%)

 MSSA

7 (20)

 MRSA

3 (8.6)

 CNS

15 (42.9)

 E. faecalis

3 (8.6)

Streptococcus spp.

7 (20)

 Patient received prior antibiotic therapy, n (%)

34 (100)

 Days of previous antibiotic treatment, median (IQR)

28 (17–35)

Prior antibiotic therapy, n (%)

 Daptomycin

24 (68.6)

 Ceftriaxone

10 (28.6)

 Linezolid

3 (8.6)

 Vancomycin

8 (22.9)

 Surgery, n (%)

12 (34.3)

 Surgery before administering DBV

11 (91.6)

Reason for DBV administration, n (%)

 Facilitate discharge

30 (88.6)

 Prior treatment failure

3 (8.6)

DBV dose, n (%)

 1000 mg (1 day), 500 mg (8 days)

10 (29.4)

 1000 mg 1 day

5 (14.7)

 1500 mg (1 day)

12 (35.3)

 1000 mg (1 day), 500 mg (8 days), 500 mg (15 days)

1 (2.9)

 1500 mg (1 day), 1000 mg (15 days)

3 (.8)

 1500 mg (1 day), 1000 mg (15 days, 30 days, 45 days)

1 (2.9)

 1000 mg (1 days), 500 mg every week/9 weeks

1 (2.9)

 1500 mg (1 days), 1000 mg every 2 weeks/10 weeks

1 (2.9)

 DBV-covered days, median (IQR)

14 (14–21)

 Clinical cure, n (%)

34 (100)

 Microbiological cure, n (%)

33 (97.1)

 Follow-up blood cultures:

17 (48.6)

 Negative follow-up blood cultures

17 (100)

IE-related death, n (%)

 During hospitalisation

0

 At 12 months

0

 Relapse, n (%)

0

 Median reduction in hospital stay (IQR)

14 (7–17)

 Total reduction, days

557

  1. MSSA methicillin-sensitive S. aureus; MRSA methicillin-resistant S. aureus, CNS coagulase-negative staphylococcus